secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0000950170-24-041846
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President
----------------------------------------------------------------------------

- Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.
- Bristow receives lump sum of $370,000 (12 months salary plus $25K) and equity continues vesting under consulting agreement.
- Thomas Keuer, COO since 2015, appointed President and principal executive officer effective April 3, 2024.
- Keuer's appointment will end upon closing of the previously announced merger with Oruka Therapeutics.
- Separation agreement includes standard release, confidentiality, non-disparagement, and arbitration clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-20240402.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-041846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer